(VIANEWS) – Shares of CELYAD ONCOLOGY (BEL 20: CYAD.BR) slid by a staggering 22.44% in 10 sessions from €0.85 to €0.66 at 11:09 EST on Tuesday, after four sequential sessions in a row of losses. BEL 20 is falling 0.04% to €3,847.85, after three consecutive sessions in a row of gains.
About CELYAD ONCOLOGY
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.63.
Volume
Today’s last reported volume for CELYAD ONCOLOGY is 15452 which is 53.98% below its average volume of 96817.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CELYAD ONCOLOGY’s stock is considered to be overbought (>=80).
More news about CELYAD ONCOLOGY (CYAD.BR).
